TLR9 and neoplasm: Despite these promising results using TLR9 agonists for glioma antitumor therapy [88], CpG-ODN treatment may not yield beneficial effects in glioma patients showing an increase in tumor size after CpG-ODN intratumoral injection in a rat glioma model [116].